Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in ...

ABS therapies target a branch of the interleukin-7 (IL7)-/interleukin-7 receptor (IL7R) pathway controlled by sIL7R, a critical amplifier of autoimmune reactions. As many as half of patients with ...

IL-17 elevation in AS MAIT cells was dependent on priming with IL-7 but not IL-23 or antigen stimulation. The AS-associated IL7R single nucleotide polymorphism (SNP), rs11742270, had no effect on ...

Background: Immune checkpoint inhibitors (ICIs) are extensively employed in cancer treatment; however, the development of ICI-associated myocarditis (ICI-MC) introduces a severe and potentially fatal ...

NANTES, France I November 4, 2024 I OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today reported positive results from the induction period of the CoTikiS randomized, double-blind, ...

First anti-IL7R mAb positive efficacy study enabling pathway of future development to potential First-in-Class Interleukin-7 antagonist in autoimmune and inflammatory diseases. NANTES, France, ...

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis ...

(E) Representative snapshots of the simulation at homeostasis showing spatial expression patterns and signaling activity of components of IL7R and Notch1 signaling pathways in TECs (top two panels) ...

For example, when they activated an enhancer that contained a genetic variant related to inflammatory bowel disease, the resulting enhancer RNA triggered upregulation of the IL7R gene. “In the ...

For example, when they activated an enhancer that contained a genetic variant related to inflammatory bowel disease, the resulting enhancer RNA triggered upregulation of the IL7R gene.